{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:45Z","timestamp":1787721645182,"version":"build-2784847793"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2024AAC04005, 2026AAC030662"],"award-info":[{"award-number":["2024AAC04005, 2026AAC030662"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016692","name":"Key Research and Development Program of Ningxia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid-associated ophthalmopathy (TAO) is an autoimmune orbital disorder characterized by orbital inflammation and hyperplasia of extraocular muscles (EOMs) and adipose tissue. Tocilizumab (TCZ) has demonstrated anti-inflammatory effects in TAO, but its ability to induce structural regression of hypertrophic EOMs has not been objectively quantified using advanced three-dimensional (3D) imaging techniques. This retrospective study aimed to evaluate the clinical and structural effects of TCZ in active moderate-to-severe TAO using quantitative 3D MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-four patients with active moderate-to-severe TAO who completed a standard four-dose TCZ regimen (8 mg\/kg every four weeks) were enrolled. Clinical parameters (Clinical Activity Score (CAS), orbital tension, proptosis) and serum biomarkers (thyrotropin receptor antibody (TRAb), interleukin-6 (IL-6) were assessed at baseline (T1), post-treatment (T2), and at one-month follow-up (T3). Structural remodeling was quantified by measuring the cross-sectional areas (CSA) of individual EOMs and orbital fat volume (OFV) using coronal 3D modified Dixon quantitative T1-weighted MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TCZ induced rapid inflammatory inactivation, with median CAS declining from 3 to 0 (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). Proptosis showed modest reduction (20.00\u00a0mm to 19.75\u00a0mm,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.020). Quantitative MRI revealed the most pronounced CSA reduction in the superior rectus (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), followed by significant decreases in the inferior and lateral recti (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05), whereas no significant changes were observed in the medial rectus CSA (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.170) or OFV (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.179). Serum TRAb significantly decreased (4.95 to 4.62 IU\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.007), while IL-6 showed a modest increase (1.50 to 2.98 pg\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.070). TCZ was well tolerated, with no severe adverse events observed. Most patients maintained clinical improvement at one-month follow-up without rebound.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TCZ is a rapid, potent, and safe intervention for active moderate-to-severe TAO. Quantitative 3D MRI provides objective evidence that TCZ selectively induces structural regression of hypertrophic EOMs, with the superior rectus showing the most pronounced response and the medial rectus exhibiting considerable resistance, which may reflect chronic structural remodeling or fibrosis-associated changes. The significant decline in serum TRAb levels further supports the systemic immunomodulatory effects of TCZ. These findings provide imaging-based evidence for the differential structural effects of TCZ on orbital tissues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1930592","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:47:23Z","timestamp":1787719643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective extraocular muscle regression following tocilizumab in active thyroid associated ophthalmopathy: a 3D MRI-based retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Fang","family":"Nan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, General Hospital of Ningxia Medical University, Xingqing District","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Ma","sequence":"additional","affiliation":[{"name":"Ningxia Aier Eye Hospital, Jinfeng District","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyu","family":"An","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunyu","family":"Piao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifan","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peoples\u2019 Hospital of Ningxia Hui Autonomous Region, The Third Affiliated Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/bf03345275","article-title":"Effects of Graves' ophthalmopathy on quality of life","volume":"27","author":"Wiersinga","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/eje-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B8","article-title":"Palmitate induced secretion of IL-6 and MCP-1 in orbital fibroblasts derived from patients with thyroid-associated ophthalmopathy","volume":"18","author":"Paik","year":"2012","journal-title":"Mol Vis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study","volume":"14","author":"Boutzios","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory graves' Orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-014-3103-3","article-title":"Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg","volume":"24","author":"Politi","year":"2014","journal-title":"Eur Radiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0438","article-title":"Patterns of extraocular muscle enlargement in graves' Orbitopathy and acromegaly","volume":"35","author":"Zajner","year":"2025","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0304-z","article-title":"T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study","volume":"33","author":"Das","year":"2019","journal-title":"Eye (Lond)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13244-024-01693-w","article-title":"Dixon MRI-based quantitative parameters of extraocular muscles, intraorbital fat, and lacrimal glands for staging thyroid-associated ophthalmopathy","volume":"15","author":"Pu","year":"2024","journal-title":"Insights Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01220.x","article-title":"The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy","volume":"54","author":"Prummel","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-007-0429-4","article-title":"The validity of estimating quadriceps volume from single MRI cross-sections in young men","volume":"100","author":"Morse","year":"2007","journal-title":"Eur J Appl Physiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/jcm10040706","article-title":"Steroid-resistant graves' Orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience","volume":"10","author":"Perez-Moreiras","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-94-024-0921-5_4","article-title":"Regulation of IL-6 in immunity and diseases","volume":"941","author":"Tanaka","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1038\/s41598-022-10043-z","article-title":"Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease","volume":"12","author":"Berger","year":"2022","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000002541","article-title":"Treatment of thyroid eye disease-associated ophthalmopathy and myopathy with intraorbital injection of 5-fluorouracil and triamcinolone acetonide","volume":"40","author":"Kupcha","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02873-0","article-title":"Quantitative T1 mapping MRI for the assessment of extraocular muscle fibrosis in thyroid-associated ophthalmopathy","volume":"75","author":"Ma","year":"2022","journal-title":"Endocrine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)63488-8","article-title":"Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes","volume":"163","author":"Koumas","year":"2003","journal-title":"Am J Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1930592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:47:37Z","timestamp":1787719657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1930592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":31,"alternative-id":["10.3389\/fendo.2026.1930592"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1930592","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1930592"}}